Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin and hydrochlorothiazide for tolvaptan-associated polyuria in ADPKD
NL-OMON25236Not yet recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of metformin and hydrochlorothiazide in autosomal dominant polycystic kidney disease (ADPKD) (6 arms), sponsored by University Medical Center Groningen. Primary endpoint: Change in 24-hour urine volume. Planned start Mar 2018; status: not yet recruiting.
02
Drugs
metforminhydrochlorothiazide
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NL-OMON25236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25236.